Africa Asia Middle East عربي Français free subscription IRIN Site Map RSS find PlusNews on facebook follow PlusNews on twitter
Global HIV/AIDS news and analysis
Advanced search
 Wednesday 12 January 2011
Weekly reports 
In-Depth reports 
Country profiles 
Fact files 
Most read 
Print report Share |
GLOBAL: India rejects ARV patent applications, saving "countless lives"

Photo: IRIN
India is the world's largest manufacturer of generic ARVs
NAIROBI, 3 September 2009 (PlusNews) - AIDS activists have praised a decision by the Indian patent office to reject patent applications for two life-prolonging antiretroviral (ARV) drugs, allowing Indian manufacturers to keep on making and exporting generic versions.

"This is fantastic news that will save countless lives in the developing world - we can now continue to access these two very effective ARVs at an affordable price," James Kamau, coordinator of the Kenya Treatment Access Movement, told IRIN/PlusNews. Many developing countries had held off ordering generic tenofovir from Indian companies in case the patent applications were approved.

India's patent office rejected applications filed by US-based manufacturer Gilead Sciences Inc for tenofovir, and Tibotec Pharmaceuticals Inc, a subsidiary of pharmaceutical giant Johnson & Johnson, for darunavir.

Cipla, the Indian generic drug maker, and several civil society groups argued that the patent applications did not meet the criteria in section 3(d) of India's Patents Act, which include proving the "enhanced efficacy" of new uses or new forms of existing products.

Indian law recognised few patent restraints before the country joined the World Trade Organisation (WTO) in 2005, allowing it to develop one of the world's largest generic drug manufacturing industries.

India is now bound by the WTO's Trade Related Aspects of Intellectual Property Rights (TRIPS), which strengthens the intellectual property rights of pharmaceutical firms, and it has had to revise its patent laws to align them with WTO standards.

More Indian manufacturers will also be able to produce the generics, leading to further competition and lower costs. In June, Brazil also rejected a patent application by Gilead for tenofovir.

The UN World Health Organization recommends tenofovir for use in first- and second-line drug regimens in resource-poor settings, while darunavir is considered an important second-line treatment option.

"The rejection of the patents on tenofovir opens up the market for new generic competitors to drive down the price of this key AIDS drug," said Michelle Childs, of the international medical charity, Médecins Sans Frontières. "The decision regarding darunavir is significant because the drug is one of the newest and most expensive of HIV/AIDS drugs."

''India has led the way ... we encourage them to keep putting their foot down and standing up to big pharmaceutical companies''
Not out of the woods yet

Yet activists warn that the battle is not yet won; Gilead has similar patent applications pending in India, and Novartis, a large Swiss pharmaceutical manufacturer, is going to the Indian Supreme Court to challenge the interpretation and application of "efficacy" by Indian courts and the patent office.

A previous attempt by Novartis to challenge Section 3(d) of India's Patents Act, 1970, was rejected by the Madras High Court in August 2007.

"India has led the way in provision of affordable medicines to people in the developing world; we encourage them to keep putting their foot down and standing up to big pharmaceutical companies," said Leonard Okello, a Ugandan AIDS activist and former head of the international HIV team at the anti-poverty NGO, ActionAid.


Theme(s): (PLUSNEWS) Care/Treatment - PlusNews, (PLUSNEWS) HIV/AIDS (PlusNews), (PLUSNEWS) Stigma/Human Rights/Law - PlusNews


[This report does not necessarily reflect the views of the United Nations]
Print report Share |
FREE Subscriptions
Your e-mail address:

Submit your request
 More on Global
HIV/AIDS: IRIN/PlusNews weekly news and analysis round-up Issue 518 for 7 January 2011
HIV/AIDS: Top 10 for 2010
HIV/AIDS: IRIN/PlusNews weekly news and analysis round-up Issue 516 for 17 December 2010
HIV/AIDS: IRIN/PlusNews weekly news and analysis round-up Issue 515 for 10 December 2010
HIV/AIDS: Does the world need more AIDS targets?
 More on Care/Treatment - PlusNews
SWAZILAND: Thembi, "Even the children, they call a person with AIDS a `rotten potato’"
ETHIOPIA: Five-year plan to halve new HIV infections
HIV/AIDS: Disability, HIV find common ground
SOUTH AFRICA: New ARV tender halves drug prices
SOUTH AFRICA: Sihle Motha, "You have this person's life in your hands"
 Most Read 
ZAMBIA: Don’t ignore the children of sex workers
EAST AFRICA: Sex workers enticed or forced into unprotected sex
UGANDA: Muslim women back condoms for HIV prevention
Back | Home page

Services:  Africa | Asia | Middle East | Film & TV | Photo | Radio | Live news map | E-mail subscription
Feedback · IRIN Terms & Conditions · Really Simple Syndication News Feeds · About PlusNews · Jobs · Donors

Copyright © IRIN 2011
This material comes to you via IRIN, the humanitarian news and analysis service of the UN Office for the Coordination of Humanitarian Affairs. The opinions expressed do not necessarily reflect those of the United Nations or its Member States. Republication is subject to terms and conditions as set out in the IRIN copyright page.